These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20536491)

  • 1. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients.
    Nybo M; Poulsen MK; Grauslund J; Henriksen JE; Rasmussen LM
    Diabet Med; 2010 Mar; 27(3):289-94. PubMed ID: 20536491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy.
    Terekeci HM; Senol MG; Top C; Sahan B; Celik S; Sayan O; Kucukardali Y; Ipcioglu O; Cagiltay E; Oktenli C; Ozata M
    Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):119-23. PubMed ID: 19053023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.
    Xiang GD; Sun HL; Zhao LS
    Diabetes Res Clin Pract; 2007 May; 76(2):199-206. PubMed ID: 17023086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes?
    Grauslund J; Rasmussen LM; Green A; Sjølie AK
    Scand J Clin Lab Invest; 2010 Apr; 70(3):188-93. PubMed ID: 20205614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
    Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
    Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
    Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
    J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women.
    Nabipour I; Kalantarhormozi M; Larijani B; Assadi M; Sanjdideh Z
    Metabolism; 2010 May; 59(5):742-7. PubMed ID: 19922962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy.
    Korzon-Burakowska A; Jakóbkiewicz-Banecka J; Fiedosiuk A; Petrova N; Koblik T; Gabig-Cimińska M; Edmonds M; Małecki MT; Węgrzyn G
    Diabet Med; 2012 Jun; 29(6):771-5. PubMed ID: 21913967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients].
    Xiang GD; Sun HL; Zhao LS; Hou J; Yue L; Xu L
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1234-7. PubMed ID: 17686254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy.
    Dave GS; Kalia K
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(5):68-78. PubMed ID: 17543235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus.
    Papanas N; Katsiki N; Papatheodorou K; Demetriou M; Papazoglou D; Gioka T; Maltezos E
    Angiology; 2011 May; 62(4):291-5. PubMed ID: 21306998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct.
    Guldiken B; Guldiken S; Turgut B; Turgut N; Demir M; Celik Y; Arikan E; Tugrul A
    Thromb Res; 2007; 120(4):511-6. PubMed ID: 17258300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus.
    González-Clemente JM; Mauricio D; Richart C; Broch M; Caixàs A; Megia A; Giménez-Palop O; Simón I; Martínez-Riquelme A; Giménez-Pérez G; Vendrell J
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):525-9. PubMed ID: 16268804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus.
    Tavintharan S; Pek LT; Liu JJ; Ng XW; Yeoh LY; Su Chi L; Chee Fang S
    Diab Vasc Dis Res; 2014 Sep; 11(5):359-62. PubMed ID: 25005034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in endothelial function and its association with plasma osteoprotegerin in hypothyroidism with exercise-induced silent myocardial ischaemia.
    Guang-da X; Hui-ling S; Jie H
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):799-803. PubMed ID: 18410551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of soluble Fas in serum from diabetic patients with neuropathy.
    Guillot R; Bringuier AF; Porokhov B; Guillausseau PJ; Feldmann G
    Diabetes Metab; 2001 Jun; 27(3):315-21. PubMed ID: 11431596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes.
    Blázquez-Medela AM; García-Ortiz L; Gómez-Marcos MA; Recio-Rodriguez JI; Sánchez-Rodríguez A; López-Novoa JM; Martínez-Salgado C
    Eur J Clin Invest; 2012 May; 42(5):548-56. PubMed ID: 22050177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The change of insulin-like growth factor-1 in diabetic patients with neuropathy.
    Guo H; Yang Y; Geng Z; Zhu L; Yuan S; Zhao Y; Gao Y; Fu H
    Chin Med J (Engl); 1999 Jan; 112(1):76-9. PubMed ID: 11593647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy.
    Bourron O; Aubert CE; Liabeuf S; Cluzel P; Lajat-Kiss F; Dadon M; Komajda M; Mentaverri R; Brazier M; Pierucci A; Morel F; Jacqueminet S; Massy ZA; Hartemann A
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4250-8. PubMed ID: 25013993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.